Test scandals dragged down pharmaceutical stock prices
Published: 2006-05-24 06:58:00
Updated: 2006-05-24 06:58:00
Ovrall pharmaceutical industry stocks have been classified as a stable item and therefore assessed with high valuation so far but the recent bio equivalency test scandal has dragged its prices down in the Korea Stock Exchange markets.
The Kosdaq market showed on May 18 that out of the total 75...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
